GlaxoSmithKline (CAI:BIOC) Total Liabilities: E£809 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Total Liabilities?

GlaxoSmithKline CAI:BIOC +20.00% Total Liabilities is E£809 Mil as of Sep. 2016.

GlaxoSmithKline's Total Liabilities for the quarter that ended in Sep. 2016 was E£809 Mil.

GlaxoSmithKline's quarterly Total Liabilities declined from Mar. 2016 (E£924.80 Mil) to Jun. 2016 (E£849.30 Mil) and declined from Jun. 2016 (E£849.30 Mil) to Sep. 2016 (E£808.81 Mil).

GlaxoSmithKline's annual Total Liabilities increased from Dec. 2013 (E£396.20 Mil) to Dec. 2014 (E£484.19 Mil) and increased from Dec. 2014 (E£484.19 Mil) to Dec. 2015 (E£763.69 Mil).

GlaxoSmithKline Total Liabilities Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Total Liabilities Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Total Liabilities
216.00 396.20 484.19 763.69

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 900.81 763.69 924.80 849.30 808.81

GlaxoSmithKline Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GlaxoSmithKline's Total Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=755.174+(0+8.511
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=764

Total Liabilities=Total Assets (A: Dec. 2015 )-Total Equity (A: Dec. 2015 )
=1766.511-1002.826
=764

GlaxoSmithKline's Total Liabilities for the quarter that ended in Sep. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=803.553+(0+5.261
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=809

Total Liabilities=Total Assets (Q: Sep. 2016 )-Total Equity (Q: Sep. 2016 )
=1880.786-1071.972
=809

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of E£809 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Total Liabilities of E£809 Mil as of Sep. 2016. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Total Liabilities too high?
GlaxoSmithKline's current Total Liabilities is E£809 Mil.
How does GlaxoSmithKline's Total Liabilities compare to PRPH?
GlaxoSmithKline's Total Liabilities of E£809 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors. GlaxoSmithKline's current Total Liabilities is E£809 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Total Liabilities of E£809 Mil. The current Total Liabilities is E£809 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Total Liabilities is E£809 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.